In Brief: House FY 1997 Budget Resolution
This article was originally published in The Gray Sheet
Executive Summary
House FY 1997 Budget Resolution: GOP leaders recommend savings of $662 mil. in FDA's budget authority through 2002 by structurally reforming the agency's "review process," according to a budget summary. The House plan assumes passage of House/Senate FDA reform legislation proposals, both of which include some type of third-party system for device review and good manufacturing practices inspections...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.